SeekingAlpha · Aug 11, 2026
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsBrian Luque - Head of Investor Relations & Corporate...
GU
NASDAQ · GUTS
Fractyl Health, Inc. Common Stock
Healthcare · Biotechnology
$0.66
Up+$0.04 (+5.71%)
Updated Aug 31, 2026, 2:24 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 166.41M
- P/E ratio
- -1.22
- Dividend yield
- 0.00%
- 52-week range
- $0.42 – $1.03
- Volume
- 2.38M
- Avg. volume
- 4.08M
Price performance
GUTS price history
1M range · 20 trading sessions · Daily adjusted prices
GUTS closed at $0.66 after 20 trading sessions, down 2.69% for the selected period.
- Last close
- $0.66
- Period change
- -2.69%
- Period low
- $0.66
- Period high
- $0.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $0.7406 | $0.759 | $0.645 | $0.659 | 2.38M |
| Aug 27, 2026 | $0.735 | $0.7699 | $0.735 | $0.7418 | 768.27K |
| Aug 26, 2026 | $0.7836 | $0.7836 | $0.7309 | $0.7371 | 1.15M |
| Aug 25, 2026 | $0.771 | $0.8099 | $0.7427 | $0.7838 | 1.63M |
| Aug 24, 2026 | $0.805 | $0.809 | $0.73 | $0.75 | 1.24M |
| Aug 21, 2026 | $0.685 | $0.81 | $0.685 | $0.78 | 3.39M |
| Aug 20, 2026 | $0.704 | $0.711 | $0.6701 | $0.6851 | 783.91K |
| Aug 19, 2026 | $0.725 | $0.7484 | $0.686 | $0.686 | 792.27K |
| Aug 18, 2026 | $0.6599 | $0.748 | $0.6599 | $0.7171 | 1.53M |
| Aug 17, 2026 | $0.68 | $0.7124 | $0.66 | $0.66 | 888.23K |
| Aug 14, 2026 | $0.677 | $0.70 | $0.6569 | $0.68 | 765.87K |
| Aug 13, 2026 | $0.6895 | $0.70 | $0.662 | $0.662 | 899.93K |
| Aug 12, 2026 | $0.703 | $0.703 | $0.6801 | $0.696 | 545.02K |
| Aug 11, 2026 | $0.64 | $0.7025 | $0.64 | $0.7018 | 1.62M |
| Aug 10, 2026 | $0.72 | $0.73 | $0.675 | $0.675 | 1.53M |
| Aug 7, 2026 | $0.697 | $0.7199 | $0.69 | $0.6996 | 1.06M |
| Aug 6, 2026 | $0.6898 | $0.7078 | $0.687 | $0.687 | 764.48K |
| Aug 5, 2026 | $0.6949 | $0.7199 | $0.685 | $0.685 | 1.44M |
| Aug 4, 2026 | $0.692 | $0.705 | $0.685 | $0.685 | 706.27K |
| Aug 3, 2026 | $0.70 | $0.7027 | $0.6772 | $0.6772 | 661.72K |
Latest GUTS news
The latest Smart Investors Daily articles mentioning GUTS.
Stock researchCompany · Overview
GUTS research
Overview
Company profile and research snapshot.
Company profile
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Buy | — |
| Jun 4, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | Canaccord Genuity | Buy | — |
| Jan 30, 2026 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of $(0.57) per share from
Yahoo · Jul 22, 2026
Fractyl Health to Participate in Upcoming Investor Events
BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: BTIG Virtual Biotechnology ConferenceFormat: One-on-one meetingsDates: July
Yahoo · Jul 16, 2026
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
